Cargando…

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Current research indicates that the next silent epidemic will be linked to chronic liver diseases, specifically non-alcoholic fatty liver disease (NAFLD), which was renamed as metabolic-associated fatty liver disease (MAFLD) in 2020. Globally, MAFLD mortality is on the rise. The etiology of MAFLD is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abou Assi, Reem, Abdulbaqi, Ibrahim M., Siok Yee, Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001129/ https://www.ncbi.nlm.nih.gov/pubmed/33806527 http://dx.doi.org/10.3390/ph14030215

Ejemplares similares

Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update
por: Abdulbaqi, Ibrahim M., et al.
Publicado: (2021)

Liquid and Solid Self-Emulsifying Drug Delivery Systems (SEDDs) as Carriers for the Oral Delivery of Azithromycin: Optimization, In Vitro Characterization and Stability Assessment
por: Abou Assi, Reem, et al.
Publicado: (2020)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials
por: Abdulbaqi, Ibrahim M, et al.
Publicado: (2016)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

Transethosomal gels as carriers for the transdermal delivery of colchicine: statistical optimization, characterization, and ex vivo evaluation
por: Abdulbaqi, Ibrahim M, et al.
Publicado: (2018)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022)

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease
por: Huang, Jiaofeng, et al.
Publicado: (2021)

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Qu, Weiyi, et al.
Publicado: (2021)

MAFLD and CKD: An Updated Narrative Review
por: Mantovani, Alessandro, et al.
Publicado: (2022)

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
por: Kaya, Eda, et al.
Publicado: (2022)

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
por: A. Razak, S. Aishah, et al.
Publicado: (2021)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
por: Buzova, Diana, et al.
Publicado: (2020)

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)—A Review
por: Różański, Gracjan, et al.
Publicado: (2021)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
por: Vos, Dyonne Y., et al.
Publicado: (2021)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
por: Sandoval-Rodriguez, Ana, et al.
Publicado: (2022)

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
por: Yang, Keungmo, et al.
Publicado: (2023)

Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation
por: Khan, Arshad Ali, et al.
Publicado: (2018)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
por: Badmus, Olufunto O., et al.
Publicado: (2022)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
por: Estévez-Vázquez, Olga, et al.
Publicado: (2021)

Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease(MAFLD)
por: Dai, Xinyi, et al.
Publicado: (2022)

A43 SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
por: Kablawi, D, et al.
Publicado: (2023)

Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
por: Drożdż, Karolina, et al.
Publicado: (2021)

MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
por: Grabherr, Felix, et al.
Publicado: (2022)

Identification of Hepatic Dendritic Cells in Liver Biopsies in Patients with Metabolic Dysfunction-Associated Fatty Liver Diseas (MAFLD) and Obesity
por: Barranco-Fragoso, Beatriz, et al.
Publicado: (2022)

A stability-indicating HPLC-UV method for the quantification of anthocyanin in Roselle (Hibiscus Sabdariffa L.) spray-dried extract, oral powder, and lozenges()
por: Khan, Nasir Hayat, et al.
Publicado: (2022)

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)
por: Bril, Fernando
Publicado: (2021)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

Non-pharmacological management options for MAFLD: a practical guide
por: Stefano, José Tadeu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3bi0c6j7laervr5jafma0ivo65